Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment.
The consequences of long-term in vivo expression of human c-mpl ligand in a mouse model were examined. Transgenic mice expressing the human full-length cDNA in the liver exhibited a fourfold increase in circulating platelet count that persisted stably over the life of the animals. Transgenic animals thrived and appeared healthy for at least 500 days. Transgenic platelets appeared normal with respect to surface antigens and response to platelet aggregation agonists. The highest-expressing transgenic line maintained human c-mpl ligand serum levels of 3 ng/mL. Megakaryocyte numbers in bone marrow and spleen were elevated, as were bone marrow and spleen megakaryocyte colony-forming cells (MEG-CFC). Megakaryocytes were observed in the bone marrow, spleen, liver, and lung, but in no other sites. Circulating myeloid and lymphoid cell populations were increased twofold. Additionally, the animals had a slight but significant anemia despite an increase in marrow colony-forming units-erythroid (CFU-E). No evidence of myelofibrosis was observed in the bone marrow. The platelet nadir in response to administration of either antiplatelet serum (APS) or 5-fluorouracil (5FU) was significantly reduced relative to the control level. Furthermore, the red blood cell (RBC) nadir was reduced relative to control levels in both models, suggesting that c-mpl ligand can directly or indirectly support the maintenance of erythrocyte levels following thrombopoietic insult.
Zhou
W
W
Amgen Inc, Thousand Oaks, CA 91320, USA.
Toombs
C F
CF
Zou
T
T
Guo
J
J
Robinson
M O
MO
D000818:Animals; D018076:DNA, Complementary / Q000235:genetics; D005472:Fluorouracil / Q000008:administration & dosage*; D015870:Gene Expression; D006801:Humans; D008533:Megakaryocytes / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D010976:Platelet Count / Q000187:drug effects; D013922:Thrombocytosis / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D013926:Thrombopoietin / Q000096:biosynthesis* / Q000235:genetics
D018076:DNA, Complementary; D010975:Platelet Aggregation Inhibitors; D013926:Thrombopoietin; D005472:Fluorouracil